Evidence from numerous mass vaccination campaigns and post-marketing safety surveillance studies consistently demonstrates that new and established vaccines have favorable safety profiles. Serious side effects and deaths are exceedingly rare, refuting the expectation that they are common outcomes of mass immunization.
The claim asserts that serious side effects and deaths are expected from mass vaccination campaigns of new vaccines. Across multiple large-scale post-marketing surveillance and safety studies for various vaccines (including meningococcal B, hepatitis B, dengue, HPV, COVID-19, and malaria), the empirical evidence overwhelmingly shows that adverse events are predominantly mild, transient, and self-limiting, while serious adverse events occur very infrequently. Therefore, the claim is refuted by the literature.